Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-05-03
2005-05-03
Nickol, G. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S139100, C424S143100, C424S145100, C530S388100
Reexamination Certificate
active
06887468
ABSTRACT:
Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
REFERENCES:
patent: 4940726 (1990-07-01), Pettit et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5008196 (1991-04-01), Connolly et al.
patent: 5036003 (1991-07-01), Olander et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5354778 (1994-10-01), Ray et al.
patent: 5521073 (1996-05-01), Davis et al.
patent: 5561122 (1996-10-01), Pettit
patent: 5569786 (1996-10-01), Pettit et al.
patent: 5587297 (1996-12-01), Jacobson et al.
patent: 5643755 (1997-07-01), Davis et al.
patent: 5650490 (1997-07-01), Davis et al.
patent: 5659013 (1997-08-01), Senger et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5677181 (1997-10-01), Parish
patent: 5730977 (1998-03-01), Ooka et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5786344 (1998-07-01), Ratain et al.
patent: 5814464 (1998-09-01), Davis et al.
patent: 5840301 (1998-11-01), Rockwell et al.
patent: 5851797 (1998-12-01), Valenzuela et al.
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5866127 (1999-02-01), Senger et al.
patent: 5874081 (1999-02-01), Parish
patent: 5874542 (1999-02-01), Rockwell et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5879672 (1999-03-01), Davis et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 5972338 (1999-10-01), Godowski et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6007817 (1999-12-01), Epstein et al.
patent: 6008319 (1999-12-01), Epstein et al.
patent: 6020473 (2000-02-01), Keyt et al.
patent: 6022541 (2000-02-01), Senger et al.
patent: 6024955 (2000-02-01), Asano et al.
patent: 6030831 (2000-02-01), Godowski et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6057435 (2000-05-01), Godowski et al.
patent: 6074873 (2000-06-01), Fong et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6121230 (2000-09-01), Charnock-Jones et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6291667 (2001-09-01), Gill et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6416758 (2002-07-01), Thorpe et al.
patent: 6524583 (2003-02-01), Thorpe et al.
patent: 20020032315 (2002-03-01), Baca et al.
patent: 0 666 868 (2002-04-01), None
patent: WO 9214748 (1992-09-01), None
patent: WO 9308210 (1993-04-01), None
patent: WO 9317715 (1993-09-01), None
patent: WO 9410202 (1994-05-01), None
patent: WO 9411499 (1994-05-01), None
patent: WO 9521868 (1995-08-01), None
patent: WO 9601653 (1996-01-01), None
patent: WO 9845331 (1998-10-01), None
patent: WO 9845332 (1998-10-01), None
patent: WO9940118 (1999-08-01), None
patent: WO 0034337 (2000-06-01), None
patent: WO 0037502 (2000-06-01), None
Supplemental European Search Report for Divisional Application 01125821.7, mailed Dec. 27, 2001.
Bodey et al, “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy,”Anticancer Res.,20:2665-2676, 2000.
Colman, “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,”In A Structural View of Immune Recognition by Antibodies, 33-36, 1994.
Spitler, “Cancer Vaccines: The Interferon Analogy,”Cancer Biotherapy, 10(1):1-3, 1995.
Abaza and Atassi, “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin,”J. Protein Chemistry, 11(5):433-444, 1992.
Attwood, “The Babel of Bioinformatics,”Science, 290(5491):471-473, 2000.
Mikayama et al., “Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor,”Proc. Natl. Acad. Sci. USA, 90:10056-10060, 1993.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,”In, The Protein Folding Problem and Tertiary Structure Prediction, Eds., Merz & LeGrand, pp. 492-495, 1994.
Voet et al., “Chemical Evolution,”In, Biochemistry I, Voet & Voet, pp. 126-234, 1990.
Connolly et al., “Human Vascular Permeability Factor,”J. Biol. Chem., 264(33):20017-20024, 1989.
Ferrara et al., “Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins,”Endocrine reviews, 13(1):18-32, 1992.
Hori et al., “Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody Against Human Basic Fibroblast Growth Factor,”Cancer Res., 51:6180-6184, 1991.
Takahashi et al., “Inhibition of Cell Growth and Tumorigenesis of Human Glioblastoma Cells by a Neutralizing Antibody Against Human Basic Fibroblast Growth Factor,”FEBS Lett., 288(1,2):65-71, 1991.
Heimbrook et al., “Transforming growth factor α-Pseudomonasexotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts,”Proc. Natl. Acad. Sci. USA,87:4697-4701, 1990.
Hirota et al., “Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody,”Cancer Research, 49:7106-7109, 1989.
Plate et al., “U-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis,”Cancer Research, 53(23):5822-5827, 1993.
Kuby, “Antigens”,Immunology, Second Edition, Chapter 4, 85-96, 1994.
Waldmann, “Monoclonal Antibodies in Diagnosis and Therapy,”Science, 252:1657-1662, 1991.
Akuzawa, et al., “Zinc Finger Transcription Factor Egr-1 Activates Flt-1 Gene Expression in THP-1 Cells on Induction for Macrophage Differentiation”,Arteriosclerosis, Thrombosis, and Vascular Biology, 20(2):377-84, 2000.
Asano, et al., “Inhibition of Tumor Growth and Metastasis by an Immunoneutralizing Monoclonal Antibody to Human Vascular Endothelial Growth Factor/Vascular Permeability Factor,”Cancer Res.,55:5296-5301, 1995.
Asano, et al., “An Anti-human VEGF Monoclonal Antibody, MV833, that Exhibits Potent Anti-tumor Activity in vivo,”Hybridoma, 17:185-90, 1998.
Baca et al., “Antibody Humanization using Monovalent Phage Fisplay,”J. Biol. Chem.,272(16):10678-84, 1997.
Benjamin, et al., “Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal,”J. Clin. Invest.,103(2):159-165, 1999.
Borgstrom, et al., “Complete Inhibition of Angiogenesis and Growth of Microtumors by Anti-vascular Endothelial Growth Factor Neutralizing Antibody: Novel Concepts of Angiostatic Therapy from Intravital Videomicroscopy,”Cancer Res.,56(17):4032-1439, 1996.
Borgstrom, et al., “Neutralizing Anti-vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors in vivo,”Prostate, 35(1):1-10, 1998.
Borgstrom, et al., “Importance of VEGF for Breast Cancer Angiogenesis in vivo: Implications from Intravital Microscopy of Combination Treatments with an Anti-VEGF Neutralizing Monoclonal Antibody and Doxorubicin,”Anticancer Research, 19(5B):4203-11, 1999.
Brekken, “Vascular Endothelial Growth Factor as a Target for the Therapy of Solid Tumors,”Ph.D. Dissertation, The University of Texas Southwestern Medical Center
Brekken Rolf A.
Thorpe Philip E.
Board of Regents , The University of Texas System
Nickol G.
Williams, Morgan and Amerson
Yaen C.
LandOfFree
Antibody kits for selectively inhibiting VEGF does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody kits for selectively inhibiting VEGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody kits for selectively inhibiting VEGF will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463687